CLINICAL AREA

A legitimate vascular research question—not a completed clinical answer

Vascular injury following infection — persistent endothelial activation, glycocalyx disruption, altered coagulation markers, permeability changes and microcirculatory dysfunction — became a visible research area after COVID-19. Several sulodexide studies measured endothelial biomarkers in that context.

What those studies do not show matters as much as what they do. Biomarker changes do not demonstrate destruction of SARS-CoV-2 spike protein, removal of vaccine-derived material, guaranteed microclot clearance, or a universal long-COVID treatment. No direct published evidence establishes any of those claims. They are a legitimate basis for further research — nothing more.

Convalescent COVID-19: the biomarker RCT

Published human trialPreliminary (single RCT, surrogate endpoints)

Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients

Gonzalez-Ochoa AJ, et al. · Clinical and Applied Thrombosis/Hemostasis, vol 31 · 2025

doi:10.1177/10760296241297647 ↗ · PMID 39763448

Design: Double-blind, single-center, randomized, placebo-controlled trial (Mexico)
Participants / model: 206 analysed (103 sulodexide / 103 placebo)
Intervention: Sulodexide 250 LRU orally twice daily for 8 weeks, in early convalescence
Comparator: Placebo
Endpoint: Endothelial-dysfunction biomarkers (thrombomodulin primary)
Result: Significantly lower thrombomodulin, von Willebrand factor and IL-6 vs placebo at week 8; D-dimer and CRP also lower; no difference in P-selectin, fibrinogen, VCAM-1 or ICAM-1.
Limitations: Single-center; surrogate biomarker endpoints, not clinical outcomes. Biomarker changes do not demonstrate spike-protein destruction, microclot removal, or a universal long-COVID treatment.
Conflicts: First author disclosed consulting for Alfasigma Mexico.

Panacea interpretation · A legitimate vascular research question — not a completed clinical answer. Supports Panacea’s dedicated post-viral endothelial-dysfunction track (pillar 5).

Early COVID-19: the outpatient RCT

Published human trialPreliminary

Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial

Gonzalez-Ochoa AJ, et al. · Thrombosis and Haemostasis, 121(7):944–954 · 2021

doi:10.1055/a-1414-5216 ↗ · PMID 33677827

Design: Randomized, placebo-controlled outpatient trial
Participants / model: 243 per-protocol (124 sulodexide / 119 placebo); intention-to-treat also reported
Intervention: Sulodexide 1000 LRU/day for 21 days, in high-risk outpatients within 3 days of symptom onset
Comparator: Placebo
Endpoint: Hospitalisation, supplemental oxygen, inflammatory and coagulation markers
Result: Hospitalisation 17.7% vs 29.4% (p=0.03); less supplemental oxygen (30% vs 42%, p=0.05); lower D-dimer >500 ng/dL rates and CRP; no differences in thromboembolic events, major bleeding or mortality.
Limitations: The authors state the results should be confirmed; no mortality or thrombosis benefit was shown.
Conflicts: First author disclosed unrelated Alfasigma Mexico research ties.

Panacea interpretation · Supports the post-viral research question; does not establish any treatment protocol.

Long COVID: the TUN-EndCOV study

Published human trialPreliminary

Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study

Charfeddine S, et al. · Frontiers in Cardiovascular Medicine, 9:866113 · 2022

doi:10.3389/fcvm.2022.866113 ↗ · PMID 35647070

Design: Multicenter prospective QUASI-EXPERIMENTAL study — not randomized, no placebo
Participants / model: 290 (144 sulodexide / 146 no-treatment control)
Intervention: Sulodexide, 21 days
Comparator: No-treatment control group
Endpoint: Endothelial quality index (EQI), chest pain, palpitations
Result: At 21 days, greater improvement in chest pain (83.7% vs 43.6%), palpitations (85.2% vs 52.9%) and endothelial quality index (median ΔEQI 0.66 vs 0.18); endothelial improvement correlated with symptom recovery.
Limitations: Quasi-experimental, non-randomized, no placebo control; 21-day follow-up. This study must never be described as an RCT.
Conflicts: None declared in the verified record.

Panacea interpretation · Interesting and hypothesis-generating; its non-randomized design is exactly why Panacea treats post-viral endothelium as an open research question.

THE FULL EVIDENCE DATABASE THE PANACEA RESEARCH PROGRAMME